Loading...
Loading...
TENX| Name | Value |
|---|---|
| Revenues | 5.8K |
| Cost of Revenue | 4.7K |
| Gross Profit | 1.1K |
| Operating Expense | 3,336.3K |
| Operating I/L | -3,340.9K |
| Other Income/Expense | 115.3K |
| Interest Income | -290.6K |
| Pretax | -3,225.6K |
| Income Tax Expense | 1,129.6K |
| Net Income/Loss | -3,225.6K |
Tenax Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. The company's product portfolio includes TNX-103 and TNX-102 (levosimendan) for the treatment of pulmonary hypertension associated with heart failure with preserved ejection fraction, and TNX-201 (imatinib), a tyrosine kinase inhibitor for pulmonary arterial hypertension. These products have completed phase II clinical trials, positioning the company to generate revenue through the successful commercialization of these treatments.
